The FDA advised consumers not to purchase or use Mezo, LX1, or Best Line Suplemento Alimenticio, all products promoted and sold for weight loss on various websites and in some retail stores.
FDA laboratory analysis confirmed that Mezo contain benzylsibutramine, a substance structurally similar to sibutramine. Analysis confirmed that Best Line Suplemento Alimenticio Capsules contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.
Laboratory analysis confirmed that LX1 contains undisclosed DMAA, also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract. Ingestion of DMAA can elevate blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest.
There is a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building and are often represented as being “all natural.”
The FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Consumers should exercise caution before purchasing any product in the categories of sexual enhancement, weight loss, and body building.
See the FDA Mezo Notice
Also see the FDA LX1 Notice
Also see the FDA Best Line Suplemento Alimenticio Notice
See also Medical Law Perspectives, November 2013 Report: Diagnosis and Treatment of Heart Attacks: Liability Issues
See also Medical Law Perspectives, May 2013 Report: Drugs, Dosage, and Damage: Physician Liability for Prescribing or Administering Medication